Special purpose acquisition company (SPAC) eureKING has agreed a deal to buy SCTbio as part of a plan to build a contract manufacturing company specialising in biologic th
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh